In France, the HPV vaccine, which protects against human papillomavirus, is recommended for all girls and boys aged 11 to 14, in 2 doses 5 to 13 months apart, with catch-up possible up to age 26 inclusive. Given before sexual activity begins, it greatly reduces the risk of precancerous lesions and cervical cancer. It does not replace cervical screening, which is still needed from age 25.
HPV vaccination is a key prevention tool in gynaecological cancer care. Human papillomaviruses (HPV) are very common viruses, passed on through intimate contact, with or without penetration. Most sexually active people will be infected at least once. In most cases, the body clears the virus naturally within a few months, without any symptoms.
When certain "high-risk" HPV types persist, they can cause abnormal changes in the cells of the cervix and then, if left untreated over several years, cancer. Persistent infection with a high-risk HPV causes almost all cervical cancers. These viruses are also involved in some cancers of the vulva, vagina, anus, penis and throat. Other types (6 and 11) cause genital warts.
The vaccine works upstream: it prevents infection with the types it contains. Together with regular screening, it is one of the pillars of prevention.
In France, vaccination has been recommended for all girls and, since 2021, all boys, and has been offered free of charge in schools, in the second year of secondary school (5e, age 11–12), since September 2023. The vaccine used for all new vaccinations is the nine-valent vaccine (Gardasil 9), which protects against 9 HPV types: 6, 11, 16, 18, 31, 33, 45, 52 and 58.
| Situation | Age | Usual schedule |
|---|---|---|
| Recommended vaccination | 11 to 14 years inclusive | 2 doses 5 to 13 months apart |
| Catch-up | 15 to 26 years inclusive, women and men (extended by the HAS in 2025) | 3 doses (month 0, month 2, month 6) |
| Weakened immune system, before or after a transplant | Based on specialist advice | Adapted schedule |
The age of 11 to 14 has nothing to do with an assumed start of sexual activity. At this age, the immune response is strongest and two doses are enough. Above all, protection is greatest when the vaccine is given before any contact with the virus.
Older French recommendations (vaccinating girls aged 14 to 23 with the four-valent vaccine) no longer apply. If a course was started with another vaccine, your doctor will tell you how to complete it.
Yes, and the evidence is now very strong:
Effectiveness therefore depends mainly on age at vaccination. In a woman already exposed to the virus, the vaccine does not treat an existing infection, but it can protect against types she has not yet encountered.
The vaccine has been used since 2006 in many countries. International monitoring and trials have not found any serious risk linked to the vaccine. The most common side effects are mild and short-lived:
The only contraindications are a severe allergy to a previous dose or to a component of the vaccine. As a precaution, vaccination is not given during pregnancy; if a pregnancy starts during the course, the remaining doses are postponed until after the birth.
Yes. Even the nine-valent vaccine does not cover all high-risk HPV types, and many women were vaccinated late or did not complete the course. In France, screening is therefore recommended in the same way for vaccinated and unvaccinated women:
To understand the test, see our article on the cervical smear test. Condoms protect against many sexually transmitted infections, but only partly protect against HPV, because the virus is present on the skin around the genitals.
The vaccine is not a treatment: it does not clear an existing lesion or an ongoing infection. After treatment of a precancerous lesion (for example a cone biopsy), whether vaccination is worthwhile to limit the risk of recurrence is discussed case by case, depending on your age and vaccination status.
At the practice, vaccination can be given during a consultation.
Would you like a medical opinion?Appointments in Paris 16th or 5th, or by video consultation.
Book an appointmentYes. In France, since 2021, vaccination has been recommended for boys as well as girls aged 11 to 14. It protects them against cancers of the anus, penis and throat and against genital warts, and it reduces the spread of the virus.
Yes, within the catch-up age limits. The benefit is slightly smaller than before any sexual contact, but the vaccine protects against the virus types you have not yet encountered.
Yes, up to and including age 26, for women and men alike, regardless of sexual orientation: this is the catch-up programme extended by the HAS in 2025. From age 15, the schedule is 3 doses (0, 2 and 6 months).
Long-term follow-up has not shown any significant decline in protection. No booster is recommended to date.
No. No study has shown any effect of the vaccine on fertility. By preventing cervical lesions, it actually helps avoid treatments such as cone biopsy, which slightly increase the risk of premature birth.
A question about your situation?Appointments at the practice or by video consultation, usually within one week to 10 days.
Book an appointmentGeneral information article: it does not replace a medical consultation. In an emergency, call 15 or 112 in France, or your local emergency number.